Sarepta Therapeutics (SRPT) Prices 6.17M Share Offering at $81/sh

Pre-Open Stock Movers 10/13: (WTRH) (KOSS) (RVNC) Higher; (RGLS) (ARDX) (STIM) Lower (more...)

October 13, 2021 9:24 AM EDT

Pre-Open Stock Movers:

Waitr Holdings (NASDAQ: WTRH) 38.5% HIGHER; Morgan Stanley files 13G

Regulus Therapeutics Inc. (Nasdaq: RGLS) 29.6% LOWER; announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Company recently completed the dosing period of the in-life portion of the IND-enabling toxicity studies for RGLS8429; anticipates submitting an Investigational New Drug application (IND); and subject to U.S. Food and Drug Administration... More

After-Hours Stock Movers 10/12: (JSPR) (VST) (QCOM) Higher; (RGLS) (STIM) (RZLT) Lower (more...)

October 12, 2021 6:11 PM EDT

After-Hours Stock Movers:

Regulus Therapeutics Inc. (Nasdaq: RGLS) 25% LOWER; announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Company recently completed the dosing period of the in-life portion of the IND-enabling toxicity studies for RGLS8429; anticipates submitting an Investigational New Drug application (IND); and subject to U.S. Food and Drug Administration (FDA) clearance, initiating a phase 1 study in the second quarter of 2022.

Neuronetics, Inc. (NASDAQ: STIM)... More

Sarepta Therapeutic (SRPT) Stock Dips 6% on $500 Million Stock Offering

October 12, 2021 4:38 PM EDT

Sarepta Therapeutics, Inc. (Nasdaq: SRPT) shares were trading more than 6% lower after-hours following the announcement of a common stock offering.

The company made an announcement, according to which it is proposing $500 million in shares of its common stock in an underwritten public... More

Sarepta Therapeutics (SRPT) Reports Prelim Q3 Revenues of $166.9M

October 12, 2021 4:05 PM EDT

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced preliminary financial results for its third quarter ended September 30, 2021.

Sarepta expects its net product revenues for the quarter... More

Sarepta Therapeutics (SRPT) Announces Proposed $500M Common Stock Offering

October 12, 2021 4:01 PM EDT

Sarepta Therapeutics, Inc. (Nasdaq: SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market and other conditions, $500,000,000 in shares of its common stock in an underwritten public offering. Sarepta also intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 in shares of its common stock.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Credit Suisse Securities (USA) LLC are acting as the underwriters of the proposed... More